FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136159512> ?p ?o ?g. }

• W2136159512 endingPage "665" @default.
• W2136159512 startingPage "660" @default.
• W2136159512 abstract "The efficacy and tolerability of the regimen containing paclitaxel and cisplatin (TP) in the neo-adjuvant treatment of locally advanced squamous cell cervical cancer are unknown. The TIP regimen (TP plus ifosfamide) showed high efficacy but high toxicity and it is used as an internal control.In all, 154 patients were randomized to TP (paclitaxel 175 mg/m(2) + cisplatin 75 mg/m(2); n = 80) or TIP (TP + ifosfamide 5 g/m(2); n = 74), three cycles, followed by radical surgery. Pathological response to chemotherapy was classified as optimal [no residual tumor (complete response) or residual disease with < or = 3 mm stromal invasion (PR1)] or suboptimal response.Patient characteristics (TP/TIP): stage IB2 (56%/64%), IIA (18%/14%), IIB (20%/19%), III-IVA (5%/4%) and median age (42 years/45 years). The optimal response rate in the TP group was 25%, 95% confidence interval (CI) = 16% to 37% and 43%, 95% CI = 31% to 55% in the TIP group. Grades 3-4 leukopenia (6%/53%) and neutropenia (26%/76%) were significantly more frequent on TIP.TP performance was below expectation since the lower 95% confidence limit of the optimal response rate failed to reach the prespecified minimum requirement of efficacy, i.e. 22%. The TIP regimen confirmed its activity but was associated with higher haematological toxicity than TP." @default.
• W2136159512 created "2016-06-24" @default.
• W2136159512 creator A5001346643 @default.
• W2136159512 creator A5010338543 @default.
• W2136159512 creator A5010454944 @default.
• W2136159512 creator A5010972450 @default.
• W2136159512 creator A5013572659 @default.
• W2136159512 creator A5017440774 @default.
• W2136159512 creator A5018539503 @default.
• W2136159512 creator A5024445482 @default.
• W2136159512 creator A5029489211 @default.
• W2136159512 creator A5029949952 @default.
• W2136159512 creator A5036510020 @default.
• W2136159512 creator A5051321693 @default.
• W2136159512 creator A5053162229 @default.
• W2136159512 creator A5056190965 @default.
• W2136159512 creator A5064140140 @default.
• W2136159512 creator A5065551274 @default.
• W2136159512 creator A5066888430 @default.
• W2136159512 creator A5070080691 @default.
• W2136159512 date "2009-04-01" @default.
• W2136159512 modified "2023-10-13" @default.
• W2136159512 title "A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study" @default.
• W2136159512 cites W2028453672 @default.
• W2136159512 cites W2096391106 @default.
• W2136159512 cites W2104522904 @default.
• W2136159512 cites W2139248078 @default.
• W2136159512 cites W4293241248 @default.
• W2136159512 doi "https://doi.org/10.1093/annonc/mdn690" @default.
• W2136159512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19181826" @default.
• W2136159512 hasPublicationYear "2009" @default.
• W2136159512 type Work @default.
• W2136159512 sameAs 2136159512 @default.
• W2136159512 citedByCount "108" @default.
• W2136159512 countsByYear W21361595122012 @default.
• W2136159512 countsByYear W21361595122013 @default.
• W2136159512 countsByYear W21361595122014 @default.
• W2136159512 countsByYear W21361595122015 @default.
• W2136159512 countsByYear W21361595122016 @default.
• W2136159512 countsByYear W21361595122017 @default.
• W2136159512 countsByYear W21361595122018 @default.
• W2136159512 countsByYear W21361595122019 @default.
• W2136159512 countsByYear W21361595122020 @default.
• W2136159512 countsByYear W21361595122021 @default.
• W2136159512 countsByYear W21361595122022 @default.
• W2136159512 countsByYear W21361595122023 @default.
• W2136159512 crossrefType "journal-article" @default.
• W2136159512 hasAuthorship W2136159512A5001346643 @default.
• W2136159512 hasAuthorship W2136159512A5010338543 @default.
• W2136159512 hasAuthorship W2136159512A5010454944 @default.
• W2136159512 hasAuthorship W2136159512A5010972450 @default.
• W2136159512 hasAuthorship W2136159512A5013572659 @default.
• W2136159512 hasAuthorship W2136159512A5017440774 @default.
• W2136159512 hasAuthorship W2136159512A5018539503 @default.
• W2136159512 hasAuthorship W2136159512A5024445482 @default.
• W2136159512 hasAuthorship W2136159512A5029489211 @default.
• W2136159512 hasAuthorship W2136159512A5029949952 @default.
• W2136159512 hasAuthorship W2136159512A5036510020 @default.
• W2136159512 hasAuthorship W2136159512A5051321693 @default.
• W2136159512 hasAuthorship W2136159512A5053162229 @default.
• W2136159512 hasAuthorship W2136159512A5056190965 @default.
• W2136159512 hasAuthorship W2136159512A5064140140 @default.
• W2136159512 hasAuthorship W2136159512A5065551274 @default.
• W2136159512 hasAuthorship W2136159512A5066888430 @default.
• W2136159512 hasAuthorship W2136159512A5070080691 @default.
• W2136159512 hasBestOaLocation W21361595121 @default.
• W2136159512 hasConcept C126322002 @default.
• W2136159512 hasConcept C126894567 @default.
• W2136159512 hasConcept C141071460 @default.
• W2136159512 hasConcept C143998085 @default.
• W2136159512 hasConcept C197934379 @default.
• W2136159512 hasConcept C2776694085 @default.
• W2136159512 hasConcept C2777063308 @default.
• W2136159512 hasConcept C2777292972 @default.
• W2136159512 hasConcept C2777506904 @default.
• W2136159512 hasConcept C2778239845 @default.
• W2136159512 hasConcept C2778375690 @default.
• W2136159512 hasConcept C2780376820 @default.
• W2136159512 hasConcept C2780873365 @default.
• W2136159512 hasConcept C2781413609 @default.
• W2136159512 hasConcept C71924100 @default.
• W2136159512 hasConcept C90924648 @default.
• W2136159512 hasConceptScore W2136159512C126322002 @default.
• W2136159512 hasConceptScore W2136159512C126894567 @default.
• W2136159512 hasConceptScore W2136159512C141071460 @default.
• W2136159512 hasConceptScore W2136159512C143998085 @default.
• W2136159512 hasConceptScore W2136159512C197934379 @default.
• W2136159512 hasConceptScore W2136159512C2776694085 @default.
• W2136159512 hasConceptScore W2136159512C2777063308 @default.
• W2136159512 hasConceptScore W2136159512C2777292972 @default.
• W2136159512 hasConceptScore W2136159512C2777506904 @default.
• W2136159512 hasConceptScore W2136159512C2778239845 @default.
• W2136159512 hasConceptScore W2136159512C2778375690 @default.
• W2136159512 hasConceptScore W2136159512C2780376820 @default.
• W2136159512 hasConceptScore W2136159512C2780873365 @default.
• W2136159512 hasConceptScore W2136159512C2781413609 @default.
• W2136159512 hasConceptScore W2136159512C71924100 @default.
• W2136159512 hasConceptScore W2136159512C90924648 @default.

• next